highly significantp = 0.55 × 10 −10
Results from the two remaining trials (LATITUDE ( NCT01715285 ) and STAMPEDE ( NCT00268476 )), representing 82% of all men randomised to AAP plus ADT versus ADT (without docetaxel in either arm), showed a highly significant 38% reduction in the risk of death with AAP plus ADT (HR = 0.62, 95% confidence interval [CI] = 0.53–0.71, p = 0.55 × 10 −10 ), that translates into a 14% absolute improvement in 3-year OS.